Back to results
US 2005/0239079 A1Published application
Predicting outcome with tamoxifen in breast cancer
AssigneeArcturus Engineering, Inc.
InventorsMark Erlander, Xiao-Jun Ma, Dennis Sgroi
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeArcturus Engineering, Inc.
InventorsMark Erlander, Xiao-Jun Ma, Dennis Sgroi
Estimating the term…
Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
An array comprising polynucleotide probes, capable of hybridizing to nucleic acid molecules of more than one of the genes in Table 1, 2, 4, and/or 5, hybridized to nucleic acids derived from one or more ER+ breast cancer cell.
A method to determine the survival outcome of an ER+ breast cancer afflicted subject if treated with tamoxifen, said method comprising assaying a sample of ER+ breast cancer cells from said subject for the expression level(s) of one or more genes in Table 1, 2, 4, and/or 5.
A method of determining prognosis of a subject having ER+ breast cancer if treated with tamoxifen, or of a subject afflicted with ER+ breast cancer and treated with tamoxifen, said method comprising:
A method to determine therapeutic treatment for an ER+ breast cancer patient based upon said patient's expected response to tamoxifen treatment, said method comprising
A method to determine the survival outcome of a human subject having ER+ breast cancer if treated with tamoxifen, said method comprising assaying a sample of breast cells from said subject for increased expression of one or more human IL17RB or CACNA1D sequences.
A method to determine the survival outcome of a human subject having ER+ breast cancer if treated with tamoxifen, said method comprising assaying a sample of breast cells from said subject for decreased expression of human HOXB13 sequences.
A population of singled stranded nucleic acid molecules comprising one or both strands of a human IL17RB or CACNA1D or HOXB13 sequence wherein at least a portion of said population is hybridized to one or both strands of a nucleic acid molecule quantitatively amplified from RNA of an ER+ breast cell.
A method to determine the survival outcome of a human subject having ER+ breast cancer if treated with tamoxifen, said method comprising assaying a sample of breast cells from said subject for increased expression of a sequence selected from SEQ ID NOS:
A method to determine the survival outcome of a human subject having ER+ breast cancer if treated with tamoxifen, said method comprising assaying a sample of breast cells from said subject for decreased expression of a sequence selected from SEQ ID NOS:
Dependencies are inferred from the claim text.